Improved pharmacokinetics and enhanced tumor growth inhibition using a nanostructured lipid carrier loaded with doxorubicin and modified with a layer-by-layer polyelectrolyte coating.
A nanostructured lipid carrier (NLC) loaded with doxorubicin (DOX) has been shown to be cytotoxic against the human cancer cell lines A549 and MCF-7/Adr. In attempts to improve formulation characteristics, enhance pharmacokinetics and antitumor effects, we modified the surface of these NLC with an alternating layer-by-layer (LbL) assembly of polycation and polyanion polyelectrolytes and an additional coating with PEG using a simple method of core shell attachment. The formulation had a narrow size distribution, longer residence in the blood, lower accumulation in the liver, higher accumulation in tumors and a significant tumor growth inhibition effect. Thus, NLC-DOX nanopreparations complexes modified by LbL coating have the potential to enhance the anticancer effects of DOX against tumors.
Center for Pharmaceutical Biotechnology and Nanomedicine, 360 Huntington Avenue, 140 The Fenway, Northeastern University, Boston, MA 02115, USA.
Samuel V
SV
Mussi
Institute for Micromanufacturing, Louisiana Tech University, Ruston, LA, USA.
Gaurav
G
Parekh
Institute for Micromanufacturing, Louisiana Tech University, Ruston, LA, USA.
Pravin
P
Pattekari
Center for Pharmaceutical Biotechnology and Nanomedicine, 360 Huntington Avenue, 140 The Fenway, Northeastern University, Boston, MA 02115, USA.
Tatyana
T
Levchenko
Institute for Micromanufacturing, Louisiana Tech University, Ruston, LA, USA.
Yuri
Y
Lvov
Department of Pharmaceutics, Faculty of Pharmacy, Federal University of Minas Gerais (UFMG), Av Antônio Carlos, 6627, Campus Pampulha, Belo Horizonte, Minas Gerais 31270-901, Brazil.
Lucas A M
LAM
Ferreira
Center for Pharmaceutical Biotechnology and Nanomedicine, 360 Huntington Avenue, 140 The Fenway, Northeastern University, Boston, MA 02115, USA; Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia. Electronic address: v.torchilin@neu.edu.
Vladimir P
VP
Torchilin
D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D004317:Doxorubicin / Q000493:pharmacokinetics / Q000494:pharmacology*; D004337:Drug Carriers / Q000737:chemistry*; D065546:Drug Liberation; D008055:Lipids / Q000737:chemistry; D051379:Mice; D008807:Mice, Inbred BALB C; D049329:Nanostructures / Q000737:chemistry*; D011073:Polyamines; D000071228:Polyelectrolytes; D011092:Polyethylene Glycols / Q000737:chemistry; D011108:Polymers; D013499:Surface Properties
D000970:Antineoplastic Agents; D004317:Doxorubicin; D004337:Drug Carriers; D008055:Lipids; D011073:Polyamines; D000071228:Polyelectrolytes; D011092:Polyethylene Glycols; D011108:Polymers
Doxorubicin; Drug delivery; In vivo; LbL; Nanostructured lipid carrier